drugset / Trial / NCT00772603

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603

Phase 3 Completed 366 enrolled Supernus Pharmaceuticals, Inc. Parexel · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures

Timeline

Start
2008-11
Primary completion
2010-04
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxcarbazepine Small molecule 1200 mg Oral
Comparator Oxcarbazepine Small molecule 2400 mg Oral

Indications